Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Gastrointestinal Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3234)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 positive
Colorectal Cancer
HER-2 positive
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
ASCO 2023 - 3 days (New C3)
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
ASCO 2023 - 3d
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
ASCO 2023 - 3 days
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
ASCO 2023 - 3 days - (New C3)
BRAF V600
Colorectal Cancer
BRAF V600
Colorectal Cancer
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days (New C3)
FORE-8394
Sensitive
:
C3
ASCO 2023 - 3d
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
FORE-8394
Sensitive
:
C3
ASCO 2023 - 3 days - (New C3)
FGFR2-BICC1 fusion
Cholangiocarcinoma
FGFR2-BICC1 fusion
Cholangiocarcinoma
pembrolizumab + pemigatinib
Sensitive: C4 – Case Studies
Front Immunol - 4 days (New C4)
pembrolizumab + pemigatinib
Sensitive
:
C4
Front Immunol - 4d
pembrolizumab + pemigatinib
Sensitive: C4 – Case Studies
Front Immunol - 4 days
pembrolizumab + pemigatinib
Sensitive
:
C4
Front Immunol - 4 days - (New C4)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
panitumumab
Sensitive: A1 - Approval
JAMA Oncol - 1 week (New C3)
panitumumab
Sensitive
:
A1
JAMA Oncol - 1wk
panitumumab
Sensitive: A1 - Approval
JAMA Oncol - 1 week
panitumumab
Sensitive
:
A1
JAMA Oncol - 1 week - (New C3)
IDH1 R132
Cholangiocarcinoma
IDH1 R132
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
Servier Press Release - 2 weeks (New A1)
ivosidenib
Sensitive
:
A1
Servier Press Release - 2wk
ivosidenib
Sensitive: A1 - Approval
Servier Press Release - 2 weeks
ivosidenib
Sensitive
:
A1
Servier Press Release - 2 weeks - (New A1)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
cetuximab + camrelizumab
Sensitive: C3 – Early Trials
Int J Cancer - 2 weeks (New C3)
cetuximab + camrelizumab
Sensitive
:
C3
Int J Cancer - 2wk
cetuximab + camrelizumab
Sensitive: C3 – Early Trials
Int J Cancer - 2 weeks
cetuximab + camrelizumab
Sensitive
:
C3
Int J Cancer - 2 weeks - (New C3)
FGFR2 amplification
Gastric Adenocarcinoma
FGFR2 amplification
Gastric Adenocarcinoma
nintedanib
Sensitive: D – Preclinical
Front Oncol - 2 weeks (New D)
nintedanib
Sensitive
:
D
Front Oncol - 2wk
nintedanib
Sensitive: D – Preclinical
Front Oncol - 2 weeks
nintedanib
Sensitive
:
D
Front Oncol - 2 weeks - (New D)
TMB-H
Pancreatic Adenocarcinoma
TMB-H
Pancreatic Adenocarcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
nivolumab + ipilimumab
Sensitive
:
A2
NCCN - 3wk
nivolumab + ipilimumab
Sensitive: A2 - Guideline
NCCN - 3 weeks
nivolumab + ipilimumab
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
FOLFIRI
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
FOLFIRI
Sensitive
:
A2
NCCN - 3wk
FOLFIRI
Sensitive: A2 - Guideline
NCCN - 3 weeks
FOLFIRI
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
OFF
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
OFF
Sensitive
:
A2
NCCN - 3wk
OFF
Sensitive: A2 - Guideline
NCCN - 3 weeks
OFF
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
Lancet Oncol - 3 weeks (New C3)
trastuzumab + tucatinib
Sensitive
:
A1
Lancet Oncol - 3wk
trastuzumab + tucatinib
Sensitive: A1 - Approval
Lancet Oncol - 3 weeks
trastuzumab + tucatinib
Sensitive
:
A1
Lancet Oncol - 3 weeks - (New C3)
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
pembrolizumab
Sensitive: A2 - Guideline
Int J Surg Case Rep - 3 weeks (New C4)
pembrolizumab
Sensitive
:
A2
Int J Surg Case Rep - 3wk
pembrolizumab
Sensitive: A2 - Guideline
Int J Surg Case Rep - 3 weeks
pembrolizumab
Sensitive
:
A2
Int J Surg Case Rep - 3 weeks - (New C4)
KRAS G12C
Pancreatic Adenocarcinoma
KRAS G12C
Pancreatic Adenocarcinoma
sotorasib
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
sotorasib
Sensitive
:
A2
NCCN - 3wk
sotorasib
Sensitive: A2 - Guideline
NCCN - 3 weeks
sotorasib
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
KRAS G12C
Pancreatic Adenocarcinoma
KRAS G12C
Pancreatic Adenocarcinoma
adagrasib
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
adagrasib
Sensitive
:
A2
NCCN - 3wk
adagrasib
Sensitive: A2 - Guideline
NCCN - 3 weeks
adagrasib
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
MSI-H/dMMR
Pancreatic Adenocarcinoma
MSI-H/dMMR
Pancreatic Adenocarcinoma
dostarlimab-gxly
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
dostarlimab-gxly
Sensitive
:
A2
NCCN - 3wk
dostarlimab-gxly
Sensitive: A2 - Guideline
NCCN - 3 weeks
dostarlimab-gxly
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
TMB-H
Colorectal Cancer
TMB-H
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
JAMA Netw Open - 3 weeks (New C3)
Immunotherapy
Sensitive
:
C3
JAMA Netw Open - 3wk
Immunotherapy
Sensitive: C3 – Early Trials
JAMA Netw Open - 3 weeks
Immunotherapy
Sensitive
:
C3
JAMA Netw Open - 3 weeks - (New C3)
ARID1A mutation
Biliary Tract Cancer
ARID1A mutation
Biliary Tract Cancer
cisplatin + gemcitabine
Resistant: C3 – Early Trials
Cancer Res Treat - 3 weeks (New C3)
cisplatin + gemcitabine
Resistant
:
C3
Cancer Res Treat - 3wk
cisplatin + gemcitabine
Resistant: C3 – Early Trials
Cancer Res Treat - 3 weeks
cisplatin + gemcitabine
Resistant
:
C3
Cancer Res Treat - 3 weeks - (New C3)
PIK3CA P449T
Colorectal Cancer
PIK3CA P449T
Colorectal Cancer
ribociclib
Sensitive: D – Preclinical
Anticancer Res - 3 weeks (New D)
ribociclib
Sensitive
:
D
Anticancer Res - 3wk
ribociclib
Sensitive: D – Preclinical
Anticancer Res - 3 weeks
ribociclib
Sensitive
:
D
Anticancer Res - 3 weeks - (New D)
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
No biomarker
Gastric Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
BRCA2 mutation
Pancreatic Cancer
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
bevacizumab + atezolizumab
Sensitive: A1 - Approval
bevacizumab + atezolizumab
Sensitive
:
A1
BRCA1 mutation
Pancreatic Cancer
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
infigratinib
Sensitive: A1 - Approval
infigratinib
Sensitive
:
A1
IDH1 mutation
Cholangiocarcinoma
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive: A1 - Approval
cetuximab + encorafenib
Sensitive
:
A1
cetuximab + encorafenib
Sensitive: A1 - Approval
cetuximab + encorafenib
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
FOLFIRI
Sensitive
:
A1
FOLFIRI
Sensitive: A1 - Approval
FOLFIRI
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login